[Maiwei Biological: subsidiary 9MW3911 injection approved Drug Clinical trial] May 9, Maiwei Biological announcement, the holding subsidiary Nuoxin received the "Drug Clinical trial approval notice" approved and issued by the State Drug Administration, and the clinical trial of 9MW3911 injection for advanced malignant tumors was approved.